What is SafeHeal?
Founded in 2015, SafeHeal specializes in the development of Colovac, a breakthrough medical device designed to eliminate the necessity for a digestive ostomy following colorectal surgery. The device functions as a flexible bypass sheath, effectively preventing fecal contact at the anastomotic site. This seamless, reversible, and minimally invasive approach allows patients to avoid the long-term physical and psychological burden of a stoma. By streamlining the recovery process and removing the requirement for secondary surgical interventions, SafeHeal is addressing a critical unmet need in gastrointestinal healthcare, positioning itself as a leader in patient-centric surgical innovation.
How much funding has SafeHeal raised?
SafeHeal has raised a total of $103.8M across 3 funding rounds:
Series A
$7.4M
Series B
$44.9M
Series C
$51.5M
Series A (2018): $7.4M, investors not publicly disclosed
Series B (2022): $44.9M led by Sofinnova Partners and Genesis MedTech
Series C (2025): $51.5M supported by Sofinnova Partners, The American Solar Eclipse, Asabys Partners, Gideon Strategic Partners, M&L Holdings Group, and M&L Healthcare Solutions
Key Investors in SafeHeal
Sofinnova Partners
A leading European venture capital firm in life sciences, Sofinnova Partners specializes in healthcare and sustainability, providing hands-on support from seed to later-stage investments.
Genesis MedTech
Headquartered in Singapore, Genesis MedTech is a specialized medical device company focused on advancing innovative healthcare technologies.
Asabys Partners
A Barcelona-based investment firm, Asabys Partners focuses on fostering breakthrough innovation in healthcare and life sciences through disruptive scientific advancements.
What's next for SafeHeal?
With the successful closure of its latest funding round, SafeHeal is poised to scale its operational footprint and expand the reach of its Colovac technology. The strategic focus will likely shift toward broader clinical adoption and regulatory milestones in key international markets. By leveraging the expertise of its diverse investor base, the company is expected to refine its manufacturing processes and enhance its commercial infrastructure. As the firm moves into this next phase of maturity, the emphasis will remain on validating the long-term clinical efficacy of its bypass sheath, ultimately aiming to establish a new standard of care that prioritizes patient quality of life and surgical efficiency.
See full SafeHeal company page
